1. Pink Sheet
  2. >>Vaccines

WHO Invites Vaccine Manufacturers to Join Fight Against Growing Mpox Outbreak

 
• By Ian Schofield

An emergency use listing means the vaccines can be approved for use in lower-income countries where they are not licensed, and will allow international organizations like Gavi and UNICEF to procure them for wider distribution.

Doctor with vial of the doses vaccine for MPOX monkeypox disease
More vaccines are needed to tackle the spread of mpox • Source: Shutterstock

The World Health Organization has triggered an emergency use listing (EUL) process for two vaccines against mpox after the current outbreak of the disease spread outside the Democratic Republic of Congo to a number of neighboring countries.

The two vaccines chosen by the WHO for the EUL process are Bavarian Nordic’s MVA-BN and KM Biologics’ LC16, which will undergo an expedited expert review once the relevant data have

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Geography

US FDA Adcomm To Consider If Genentech’s Columvi Study Generalizable To US

 
• By Sue Sutter

Patients from Asia saw a differential treatment effect versus non-Asian regions in the Phase III multiregional study, with an adverse survival trend seen in the latter group, the FDA said about the lymphoma drug.

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.